Clinical Advances in Psoriasis
The treatment of psoriasis has advanced substantially due to therapies that target key immune pathways involved in disease pathophysiology. As the therapeutic options for psoriasis expand, members of the healthcare team need a better understanding of how to use various medications and where they can be most optimally used. Patients and clinicians have set their sights on clear skin and minimal disease impact on quality of life as treatment goals. Partnership and shared decision making are increasingly important to achieve these goals in the management of psoriasis.
Supported by an independent educational grant from
Ortho Dermatologics, a division of Bausch Health
Steering Committee Co-Chair
Professor
Chairman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York
Steering Committee Co-Chair
Chairman of Dermatology
Baylor University Medical Center Dallas
Dallas, Texas
Nurse Practitioner, Dermatology
VA Portland Healthcare System
Portland, Oregon
Professor of Dermatology
Associate Dean for Clinical Research
Director of Clinical Research Support
Southern California Clinical and Translational Science Institute (SC CTSI)
Vice Chair and Director, Clinical Trials and Outcomes Research
Director, Psoriasis Program
Department of Dermatology
Keck School of Medicine at USC
University of Southern California
Los Angeles, California
Professor
Chair
Department of Dermatology
University of Alabama at Birmingham
Professor
Chair
Program Director
Eastern Virginia Medical School
Norfolk, Virginia